Peter Martin, M.D.

Hematology
Peter Martin

Our goal is to provide the best care possible for every person with lymphoma.  We are working every day to develop better treatments and integrate them into clinical practice.

Our approach involves a comprehensive team of cancer-care specialists. I believe that every person is unique, and I strive to develop a treatment plan that is individualized to each patient's needs. I am fortunate to work in a center where we can offer a range of therapies, including targeted therapies, immunotherapy, chemotherapy, radiation therapy, and stem cell transplantation.

I believe that everyone should have the opportunity to participate in a clinical trial. As a result of clinical trials open at Weill Cornell Medical College, our patients have had access to new treatments years before they became widely available. We have been involved in the development of virtually every drug approved for treatment of lymphoma over the past 15 years. The drug ibrutinib was approved for treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia, and it is under investigation in other lymphomas (diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and Waldenstrom's macroglobulinemia). The drug idelalisib is approved for treatment of patients with chronic lymphocytic leukemia and follicular lymphoma and continues to be evaluated in other areas. Lenalidomide is approved for treatment of previously treated mantle cell lymphoma and is now being evaluated as first-line therapy in follicular lymphoma and mantle cell lymphoma. I am excited that we can offer these and other promising treatments and I am looking forward to a future where we have a personalized treatment for everyone.

Dr. Peter Martin is an Assistant Professor of Medicine in the Division of Hematology/Oncology at Weill Cornell Medical College. A graduate of University of Alberta Medical School, Dr. Martin completed his residency in internal medicine and fellowship in hematology at McGill University. Prior to joining the faculty at Weill Cornell Medical College, he completed a Master's Degree in Clinical Investigation and Translational Research at the Weill Cornell School of Graduate Sciences.

Dr. Martin specializes in caring for patients with lymphoma. He is the Director of the Weill Cornell Clinical Research Program in Lymphoma. His research focuses on the clinical investigation of new and promising therapies, and he passionately believes that clinical trials are the gateway to a better future. In addition to being an investigator on clinical trials, Dr. Martin is the director of the Waterfall Waldenstrom's Macroglobulinemia Consortium and the Weill Cornell Lymphoma Database. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the Alliance for Clinical Trials in Oncology (ACTION, formerly Cancer and Leukemia Group B (CALGB)). He is board certified in Hematology and Internal Medicine by the American Board of Internal Medicine and the Royal College of Physicians and Surgeons of Canada. He has received awards and funding from the National Cancer Institute, the National Cancer Institute of Canada, the Leukemia and Lymphoma Society, the Lymphoma Research Foundation, the American Society of Hematology, and the American Society for Clinical Oncology for his research.

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [PPO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • CIGNA
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Insurance Plan of NY (HIP)
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicaid
  • Medicare
  • Medicare [Medicare]
  • Oscar
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Freedom]
  • POMCO
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]

Publications

  1. Martin P, Furman RF, Coleman M, Leonard JP. Phase I-III Trials of Anti-B Cell Therapy in Non-Hodgkin’s Lymphoma. Clin Cancer Res, 2007;13:5636s-5642 PMID 1787580
  2. Martin P, Leonard JP. Targeted Therapies for Non-Hodgkin’s Lymphoma: Rationally Designed Combinations. Clin Lymphoma Myeloma, 2007;7:S192-S198 PMID 17877844
  3. Martin P, Leonard JP. Novel Therapeutic Targets in Mantle Cell Lymphoma. Expert Opin Ther Targets, 2007;11(7):929-940 PMID 17614761
  4. Martin P, Leonard JP. IL-4 as therapy for non-Hodgkin’s lymphoma:  possibilities but major challenges. Leukemia and Lymphoma, 2007;48(7):1259-1260
  5. Leonard JP, Ruan J, Martin P, Coleman M, Furman RR. New Agents in Development for Non-Hodgkin’s Lymphoma. Seminars in Hematology, 2007;44S18-S21
  6. Coleman M, Martin P, Ruan J, Furman RR, Niesvisky R, Elstrom R, Lee C, George P, Leonard JP, Kaufman T. Lose Dose Metronomic, Multidrug Therapy with the PEP-C (Prednisone, Etoposide, Procarbazine, and Cyclophosphamide) Oral Combination Chemotherapy Regimen for Mantle Cell Lymphoma. Leukemia and Lymphoma, 2008;49(3):447-50
  7. Coleman M, Martin P, Ruan J, Furman RR, Niesvisky R, Elstrom R, George P, Kaufman TP, Leonard JP. The PEP-C (Prednisone, Etoposide, Procarbazine, and Cyclophosphamide) Oral Combination Chemotherapy Regimen for Relapsing/Refractory Lymphoma: Low Dose Metronomic, Multidrug Therapy. Cancer, 2008;112(10):2228-2232 PMID 18338745
  8. Martin P, Furman RR, Ruan J, Elstrom R, Barrientos J, Niesvizky R, Coleman M, Leonard JP. Novel and Engineered Anti-B cell Monoclonal Antibodies for Non-Hodgkin Lymphoma. Seminars in Hematology, 2008;45(2):126-132 PMID 18381108
  9. Rutherford S, Andemariam B, Philips S, Elstrom R, Chadburn A, Furman RR, Niesvizky R, Martin P, Fahey T, Coleman M, Goldsmith S, Leonard JP. FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leukemia and Lymphoma, 2008;49(4):719-26 PMID 18398739
  10. Martin P, Chadburn A, Christos P, Furman RR, Ruan J, Joyce M, Glynn P, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles D, Chen-Kiang S, Coleman M, Leonard JP. Intensive Treatment Strategies May Not Provide Superior Outcomes in Mantle Cell Lymphoma: Overall Survival Exceeding Seven Years with Conservative Therapies. Ann Oncol, 2008;19:1327-1330
  11. Leonard JP, Martin P, Ruan J, Elstrom R, Barrientos J, Coleman M, Furman RR. New monoclonal antibodies for non-Hodgkin’s lymphoma. Ann Oncol, 2008; 19(Suppl 4):iv60-iv62
  12. Leonard JP, Martin P, Barrientos J, Elstrom R. Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin Hematol, 2008; 45(suppl 2):S1-S16 PMID 18760704
  13. Estrom R, Martin P, Leonard JP. New biologic agents and immunologic strategies. Hematology/Oncology Clinics of North America, 2008;22(5):1037-1049 PMID 18954750
  14. Czuchlewski D, Csernus B, Bubman D, Hyjek E, Martin P, Chadburn A, Knowles DM, Cesarman E. Expression of the follicular lymphoma variant translocation 1 gene in diffuse large B-cell lymphoma correlates with subtype and clinical outcome. Am J Clin Pathol, 2008;130(6):957-62
  15. Martin P, Coleman M, Leonard JP. Progress in Mantle Cell Lymphoma. J Clin Oncol, 2009; 27(4):481-483 PMID 19075257
  16. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, DiLiberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Outcome of deferred initial therapy in mantle cell lymphoma. J Clin Oncol, 2009;27(8):1209-13 PMID 19188674
  17. Mark T*, Martin P*, Leonard JP, Niesvizky R. Milatuzamab: A Promising New Agent for the Treatment of Lymphoid Malignancies. Expert Opin Investigational Drugs, 2009;18(1):99-104 PMID 19053886 *co-first author
  18. Martin P, Leonard J, Furman R. Durable complete remissions in HIV-associated Hodgkin Lymphoma following treatment with only one cycle of chemotherapy complicated by sepsis. Clin Lymphoma Myeloma, 2009;9(3):247-9 PMID 19525196
  19. Martin, P. Is there a role for bone scan for Hodgkin lymphoma in the age of FDG-PET? Leukemia and Lymphoma, 2009;50(11):1731-1732
  20. Song Z, Lu P, Furman RR, Leonard JP, Martin P, Tyrell L, Lee FY, Knowles DM,  Coleman M, Wang L. Activity of SYK and PLC2 Predict Apoptotic Response of Chronic Lymphocytic Leukemia Cells to SRC Tyrosine Kinase Inhibitor Dasatinib. Clin Cancer Res, 2010;16(2):587-599 PMID 20068106
  21. Elstrom R, Martin P, Ostrow K, Barrientos J, Chadburn A, Furman R, Ruan J, Shore T, Schuster M, Cerchietti L, Melnick A, Coleman M, Leonard JP. Response to second line therapy defines potential for cure in patients with recurrent diffuse large B cell lymphoma (DLBCL): Implications for development of novel therapeutic strategies. Clin Lymphoma Myeloma, 2010;10(3):192-196 PMID 20511164
  22. Link B, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP. Cyclophosphamide, vincristine, and prednisone (CVP) followed by tositumomab and iodine-131 tositumomab in patients with untreated low-grade follicular lymphoma: eight year follow-up of a multicenter phase II study. J Clin Oncol, 2010; 28(18):3035-3041 PMID 20458031
  23. Martin P. When 18-fluorodeoxyglucose-positron emission tomography is indeterminate, the International Prognostic Index is the answer. Leukemia and Lymphoma, 2010;51(4):569-570
  24. Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A, Elstrom R, Lachs M, Hajjar KA, Leonard JP. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer, 2010;116(11):2655-2664 PMID 20235190
  25. Thompson CA, Charlson ME, Schenkein E, Wells MT, Furman RR, Elstrom R, Ruan J, Martin P, Leonard JP. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol 2010;21(11):2262-2266
  26. Furman RR, Martin P, Ruan J, Cheung YK, Vose JM, LaCasce AS, Elstrom RE, Coleman M, Leonard JP. Phase I trial of bortezomib plus R-CHOP in previously untreated aggressive non-Hodgkin lymphoma. Cancer 2010;116(23):5432-5439 PMID 20665890
  27. Leonard JP, Martin P. Novel agents for follicular lymphoma. Hematology 2010;2010:259-264 PMID 21239803
  28. Ruan J, Martin P, Furman RR, Lee SH, Cheung K, Vose JM, LaCasce A, Morrison J, Elstrom R, Ely S, Chadburn A, Cesaman E, Coleman M, Leonard JP. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). J Clin Oncol 2011;29(6):690-697 PMID 21189393
  29. Martin P, Leonard JP. Advancing through maintenance in mantle cell lymphoma. Leukemia and Lymphoma 2011;52(9)1617-1618 PMID 21699376
  30. Martin P, Leonard JP. Is there a role for “watch and wait” in patients with mantle cell lymphoma? Seminars in Hematology 2011;48(3):189-193 PMID:21782061
  31. Elstrom RL, Martin P, Hurtado Rua S, Shore TB, Furman RF, Ruan J, Pearse RN, Coleman M, Mark T, Leonard JP, Gergis U. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol. 2012;87(4):433-435
  32. Bennani-Baiti N, Daw H, Cotta C, Martin P, Mitchell KW, Ambinder RF, Macklis R, Pollock R, Spiro T. Low grade follicular lymphoma of the small intestine. A challenge for management. Seminars in Oncology. 2011;38(6):714-720 PMID:22082756
  33. Lee SM, Hershman DL, Martin P, Leonard JP, Cheung YK. Toxicity burden score: a novel approach to summarize multiple toxic effects. Ann Oncol 2012;23(2):537-541 PMID 21536663
  34. Martin P. CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1: biomarkers in search of validation in lymphomas. Leuk Lymphoma. 2012;53(1):1-2 PMID:22035419
  35. Elstrom RL, Andemariam B, Martin P, Ruan J, Shore TB, Coleman M, Leonard JP, Furman RR. Bortezomib in combination with R-DICE chemoimmunotherapy (VIPER) in patients with relapsed and primary refractory diffuse large B cell lymphoma. Leuk Lymphoma. 2012 [epub ahead of print] PMID 22263572
  36. Leonard JP, LaCasce AS, Smith M, Noy A, Chireac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Larson SM, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI. Selective CDK 4/6 inhibition and tumor responses are induced by PD0332991 in patients with mantle cell lymphoma. Blood. 2012;119(20): 4597-4607. PMID 22383795
  37. Coleman M, Ruan J, Elstrom RL, Martin P, Leonard JP. Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low dose oral combination chemotherapy regimen. Hematology. 2012;17 Suppl 1:90-92. PMID 22507790
  38. Martin P, Rutherford S, Leonard JP. Splenic lymphomas: is there still a role for splenectomy? Oncology. 2012;2:204-206. PMID 22489357
  39. Martin P, Smith M, Till B. Management of mantle cell lymphoma in the elderly. Best Practice & Research Clinical Haematology. 2012;25(2):221-231 PMID 22687458
  40. Shah BD, Martin P, Sotomayor EM. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer Control 2012;19(3):227-235 PMID 22710898
  41. Morawa E, Martin P, Gergis U, van Besien K, Shore T. Autologous stem cell transplantation in HIV-positive patients with lymphoid malignancies: focus on infectious complications. Leuk Lymphoma 2013;54(4)885-886. PMID: 22897727
  42. Chitta KS, Paulus A, Ailawadhi S, Foster BA, Moser MT, Starostik P, Masood A, Sher T, Miller KC, Iancu DM, Conroy J, Nowak NJ, Sait SN, Personett DA, Coleman M, Furman RR, Martin P, Ansell SM, Lee K, Chanan-Khan AA. Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia. Leuk Lymphoma 2013;54(2):387-396. PMID: 22812491
  43. Martin P, Shah B. Limited-stage mantle cell lymphoma: not so different from advanced stage. Leuk Lymphoma 2013;54(2):217-218. PMID: 22988842
  44. Chiron D, Martin P, Di Liberto M, Huang X, Ely S, Lannutti BJ, Leonard JP, Mason CD, Chen-Kiang, S. Induction of prolonged early G1 arrest by CDK4/CD6 inhibition reprograms lymphoma cells for durable PI3Kd inhibition through PI3KIP1. Cell Cycle. 2013;12(12):1892-900. PMID: 23676220
  45. Hsi E, Martin P. Indolent mantle cell lymphoma. Leuk Lymphoma, 2014;55(4):761-767 PMID 23927395
  46. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle cell lymphoma. N Engl J Med. 2013;369(6):507-516. PMID 23782157
  47. Clozel T, Yang SH, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakuma A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, Godley LA, Gascoyne RD, Borden KL, Inghirami G, Leonard JP, Melnick A, Cerchietti L. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discovery. 2013;3(9):1002-1019 PMID 23955273
  48. Martin P, Dawson K, Byrtek M, Zimiecki R, Friedberg J, Cerhan J, Flowers C, Link BPatterns of Delivery of Chemoimmunotherapy to Patients with Follicular Lymphoma in the United States: Results of the National LymphoCare Study. Cancer. 2013;119(23):4129-4136 PMID 24006256
  49. Hosein P, Maragulia JC, Salzberg MP, Press OW, Habermann TH, Vose JM,  Bast M, Advani RH, Tibshirani R, Evens AM, Islam N, Leonard JP, Martin P, Zelenetz AD, Lossos IS. A multicenter clinical-pathologic study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol 2014 Br J Haematol 2014;165(3):358-363. PMID: 24467658.
  50. Tang T, Martin P. The role of ibrutinib for the treatment of mantle cell lymphoma in the elderly. International Journal of Hematologic Oncology. 2013 Accepted. PMID 25023397
  51. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KB, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. N Engl J Med 2014;370(11):1008-1018. PMID: 24450858
  52. Ruan J, Gregory SA, Christos P, Martin P, Furman RR, Coleman M, Leonard JP. Long-Term Follow-Up of R-CHOP With Bevacizumab as Initial Therapy for Mantle Cell Lymphoma: Clinical and Correlative Results. Clin Lymphoma Myeloma Leuk 2014;14(2):107-113. PMID 24373788
  53. Elstrom R, Ruan J, Christos P, Martin P, Lebovic D, Osborne J, Goldsmith SJ, Greenberg J, Furman RR, Chapman E, Avram A, Putman R, Mazumdar M, Griffith K, Coleman M, Leonard JP, Kaminski M. Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin’s lymphoma receiving radioimmunotherapy with 131I-tositumomab. Leuk Lymphoma, 2014 [Epub ahead of print]. PMID 24730538.
  54. Ma J, Lu P, Guo A, Cheng S, Zong H, Martin P, Coleman M, Wang L. Characterization of ibrutinib-sensitive and –resistant mantle lymphoma cells. Br J Haematol. Published on-line June 24, 2014. PMID 24957109
  55. Tang T. Martin P. When indolent follicular lymphoma is not indolent. Leukemia and Lymphoma. Accepted. PMID 24882260
  56. Chiron D*, Di Liberto M*, Martin P*, Blecua P, Sharman J, Mathew S, Vijay P, Huang X, Eng K, Ali S, Chang B, Ely S, Elemento O, Mason CE, Leonard JP, Chen-Kiang S. Cell Cycle Reprogramming for PI3K Inhibition Overrides Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma. Cancer Discovery. Published on-line July 31, 2014. *co-first author
  57. Jiang Y, Redmond D, Nie K, Eng KW, Clozel T, Martin P, Tan LHC, Melnick AM, Tam W, Elemento O. Deep-sequencing Reveals Clonal Evolution Patterns and Mutation Events Associated with Relapse in B Cell Lymphomas. Genome Biology. Accepted.
  58. Assouline S, Chang J, Cheson BD, Rifkin R, Hamburg S, Reyes R, Hui A, Yu J,  Gupta N, Di Bacco A, Shou Y, Martin P. Phase 1 dose-escalation study of once-weekly IV MLN9708, an investigational proteasome inhibitor, in patients with relapsed or refractory lymphoma. Blood Cancer Journal. Accepted.

Honors and Awards

Dr. Ronald Oakley Prize in Anatomy, 1998

Diane Dompe Memorial Scholarship in Medicine for Merit in Medical Oncology, 2001

National Cancer Institute of Canada Terry Fox Fellowship, 2007

Swiss League Against Cancer Travel Award, 2008

Leukemia and Lymphoma Special Fellow in Clinical Research, 2009

American Society of Clinical Oncology Young Investigator Award, 2009

The Charles, Lillian and Betty Neuwirth Clinical Scholar in Oncology, 2013